Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

FDA Orders Gilead for Second Time to Stop Downplaying Risks, Inflating Benefits of Antiretroviral Drug Viread

August 8, 2003

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

The FDA for the second time in little more than a year has ordered Gilead Sciences to stop downplaying the risks and inflating the benefits of its antiretroviral drug Viread, the Los Angeles Times reports (Douglass, Los Angeles Times, 8/8). Thomas Abrams, director of the FDA's division of drug marketing, advertising and communications, wrote in a July 29 letter to Gilead that the company's representatives at an early April AIDS conference failed to disclose the risks of acid accumulation and severe liver enlargement associated with Viread and claimed that the drug could be used in a broader range of patients than the group of patients for whom it is approved (Beasley, Reuters, 8/7). Representatives at the conference exhibit said that Viread is more potent, has fewer side effects and is safer than similar antiretroviral drugs, claims which Abrams says there are no "data from head-to-head clinical trials to substantiate." Abrams said that the representatives' actions are "particularly troubling" because the company had been issued a similar warning in March 2002 (Los Angeles Times, 8/8). The FDA in a March 14, 2002, letter criticized the company over statements made by its representatives to physicians attending a scientific conference in December 2001. The FDA said that Gilead representatives told doctors that Viread has "no toxicities" and is a "miracle drug" (Kaiser Daily HIV/AIDS Report, 3/27/2002). The company is required to respond to the FDA in writing by Aug. 12 with details of its plans to identify and correct violations and to retrain its sales force. Failure to respond could result in regulatory action, including seizure and injunction, according to the letter. Gilead spokesperson Amy Flood said that the company believes the violations were an "isolated incident," adding that Gilead takes the FDA's concerns "very seriously." Flood said that the company will be "working to respond to the FDA" (Reuters, 8/7).

Investor's Business Daily Examines Future Product
Investor's Business Daily today profiles Gilead's efforts to compete in the antiretroviral drug market, including its efforts to gain approval for its Viread-Emtriva combination pill, which the company hopes to launch by 2005. The full article is available online (Lau, Investor's Business Daily, 8/8).

Back to other news for August 8, 2003


Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2003 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
 
See Also
More on HIV Medications
More News on Tenofovir (Viread)

Tools
 

Advertisement